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Abstract
The passage of the Genetic Information Non Discrimination Act (GINA) was hailed as a pivotal 
achievement that was expected to calm the fears of both patients and research participants about 
the potential misuse of genetic information. However, six years later, patient and provider 
awareness of legal protections at both the federal and state level remains discouragingly low, 
thereby, limiting their potential effectiveness. The increasing demand for genetic testing will 
expand the number of individuals and families who could benefit from obtaining accurate 
information about the privacy and anti-discriminatory protections that GINA and other laws 
extend. In this paper we describe legal protections that are applicable to individuals seeking 
genetic counseling, review the literature on patient and provider fears of genetic discrimination 
and examine their awareness and understandings of existing laws, and summarize how genetic 
counselors currently discuss genetic discrimination. We then present three genetic counseling 
cases to illustrate issues of genetic discrimination and provide relevant information on applicable 
legal protections. Genetic counselors have an unprecedented opportunity, as well as the 
professional responsibility, to disseminate accurate knowledge about existing legal protections to 
their patients. They can strengthen their effectiveness in this role by achieving a greater 
knowledge of current protections including being able to identify specific steps that can help 
protect genetic information.
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Introduction
Significant advances in genomic technology are rapidly expanding the number and scope of 
genetic tests available both for diagnosing existing disorders and for predicting treatable 
ones before the onset of symptoms. Public awareness of genetic testing options has been 
most recently heightened by news stories reporting Angelina Jolie’s decision to have 
prophylactic surgery after her testing revealed a BRCA1 gene mutation (Jolie 2013) and by 
the recent, controversial Supreme Court ruling on gene patents (AMP et al. v. Myriad 
Genetics, Inc et al. 2014). There is growing interest in and demand for genetic testing as 
treatment options expand, the cost of using newer sequencing technologies declines, the 
insurance coverage for testing widens, and the population for whom testing is recommended 
broadens.
Ironically, as genetic testing becomes an increasingly powerful diagnostic and prognostic 
tool, health care providers and their patients remain wary of the potential of genetic testing 
to trigger discrimination. Limited awareness of the true scope of legal protections afforded 
by legislation including the Genetic Information Nondiscrimination Act (GINA) persists and 
is still fueling fears of genetic discrimination by both patients and their health care providers 
nearly six years after the law’s passage (Huntsman Cancer Institute Survey, 2014). Genetic 
counselors can play an influential role in increasing awareness about these legal protections, 
both because they are more knowledgeable about them than most other health care providers 
and because their patients can derive direct benefits from this knowledge. Correcting 
patients’ common misconceptions about this topic is, in and of itself, an admirable goal but 
genetic counselors could further expand their influence by learning how their patients can 
take specific steps to help prevent discrimination. Yet counselors may find it difficult to 
attain an adequate understanding of the legal protections, and their limitations, because the 
combination of state and federal laws have created a patchwork of protections that vary 
between individuals and their family members depending upon their circumstances. Though 
these laws continue to have lingering gaps, patients and their health care providers, 
including genetic counselors, could benefit from a greater knowledge of the breadth of 
protections that are currently in place.
Patient fear of genetic discrimination has been reported with the application of genetic 
technologies to patient care (Lapham 1996, Hall 2005, Allain 2012). Despite widespread 
apprehension that genetic information will inevitably be misused, there is limited, 
convincing, empirical evidence that discrimination on the basis of genetic information has 
occurred (Hall 2005, Pollitz 2007). Whether the lack of evidence stems from under 
reporting, confusion about what constitutes illegal discrimination, or if it is a true reflection 
of the situation, is unclear (Sharpe 2006). The discrepancy between the magnitude of patient 
concern over potential misuse on one hand and the limited evidence of its occurrence on the 
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other hand, may leave genetic counselors uncertain as to which and how much information 
they should provide to their patients about the potential for discrimination (Pamarti 2011). 
This uncertainty can be encapsulated by the following questions: How can a genetic 
counselor best summarize the legal protections and their caveats and yet acknowledge the 
limited evidence of discriminatory practices in a time-sensitive manner and without causing 
patient distress? Which resources can a genetic counselor recommend to a patient who 
expresses concerns about discrimination? What actions can a patient take if he or she 
experiences discrimination?
The goal of this paper is to illustrate elements of the legal protections against genetic 
discrimination that are applicable to issues that arise during a counseling session. We first 
summarize research findings about fears of genetic discrimination among health 
professionals and the public, review their understandings of the laws banning discrimination, 
and describe the current practice of discussing the possibility of discrimination during a 
counseling session. We then present three genetic counseling cases to highlight ways that 
issues of genetic discrimination can arise during a session and provide the relevant 
background information on the applicable legal protections.1
Genetic Discrimination and Genetic Counseling Practice
Fears of Genetic Discrimination
As genetic technologies have become integrated into clinical care, patients and health care 
providers have consistently raised alarms about how certain actors – most notably insurers 
and employers – could potentially use genetic information (Pollitz 2007, Bombard 2012). In 
2000, reasoning that health care professionals could be expected to be more knowledgeable 
than patients about the validity of the potential threat, Matloff et al. conducted a survey of 
cancer genetic professionals and found that 26% would use an alias for genetic testing 
because of their concern about discrimination (Matloff 2000). By contrast, in a 2013, post-
GINA version of the study, these percentages had plummeted almost tenfold; from 26% to 
3.2% (Matloff 2013).
It remains to be seen if and to what extent patients’ fears of discrimination might also be 
alleviated by increased awareness of existing laws. In a post-GINA study, many patients still 
favored anonymous testing out of fear of discrimination related to life insurance (42.7%), 
health insurance (30%), or employment (29.1%)(Ader 2009). Fears of discrimination have 
been reported most commonly when the symptoms of a genetic condition begin in adulthood 
but they appear to have little influence on genetic testing decisions made in prenatal and 
pediatric settings. Possible explanations for this difference could be that children are 
typically symptomatic when tested, and, if they have health insurance, they are usually 
covered under their parents’ policies or by the state. Furthermore, their employability is not 
usually a pressing concern (Hall 2000). Prior to federal legal protections, evidence that fears 
of discrimination were scaring patients away from clinical genetic testing and from 
1This article presents general information about the law in order to educate genetic counselors about legal protections regarding 
genetic discrimination. It is not legal advice. Professional legal advice should always be sought before any legal action is taken. 
Application of the law may vary across situations because it is dependent on individually specific circumstances and on the applicable 
state and federal law.
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participating in genetic research (Hall 2000, Hadley 2003), led to efforts that, in 2008, 
resulted in the passage of GINA.
Broadly speaking, GINA prohibits employers and health insurance companies from 
discriminating against an individual based on his or her genetic information. Importantly, 
these entities are not allowed to collect genetic information in order to use it to raise 
premium rates, deny coverage, or make adverse employment determinations. Health 
insurance companies are permitted to request limited genetic information when it involves 
their decision about whether or not to pay for a medical procedure (GINA, 2008).
Overall, GINA has greatly improved protections for many individuals in the US not only by 
prohibiting some forms of genetic discrimination but, also, although this facet remains less 
well-recognized, by transferring to patients a much greater control over who has access to 
their genetic information. Despite these significant gains, the prudent genetic counselor will 
paint a balanced picture of the current legal landscape – acknowledging both the gaps in the 
law as well as the uncertainty about how often genetic discrimination occurs. But counselors 
should also be careful not to undersell the law’s substantial benefits.
Genetic Counselor, Public, and Physician Knowledge of GINA
During a session, genetic counselors attempt to provide a balanced portrayal of both the 
benefits and the gaps of existing protections; however, the crazy quilt of laws is complicated 
and requires general knowledge about the law as well as its specific provisions. Genetic 
counselors are quite well informed about GINA’s general protections. A recent survey by 
Pamarti reported that 99.3% knew that GINA protects against health insurance 
discrimination; however, many fewer were knowledgeable about specific details of the law 
(Pamarti 2011). For example, only 44.2% of the 257 counselors in this survey knew that 
GINA does not apply to symptomatic individuals and only 33.8% knew about the 
implications for direct-to-consumer genetic testing (Pamarti 2011). Thus, although genetic 
counselors are aware that GINA offers protection, they may not fully appreciate some of the 
potential applications to specific situations that they may encounter in their practice. 
Additionally, because the aforementioned survey only measured counselor knowledge about 
GINA’s anti-discrimination provisions, it did not assess what they knew, or didn’t know, 
about the act’s privacy protections; a less well-recognized facet of the law that has direct 
applications to individuals with a family history of a genetic condition.
Genetic counselors may have some knowledge gaps about GINA’s specific protections but a 
much higher percentage of genetic counselors are aware of the law’s existence and its 
general provisions as compared to people in the general population (AMA 2013). In the 
previously described survey, genetic counselors estimated that only about 15% of their 
patients were aware of GINA prior to their discussion of it during the counseling session 
(Pamarti 2011). This limited public awareness is corroborated by other surveys that directly 
measured public knowledge of either the existence of GINA or the existence of laws 
protecting the privacy of genetic information. In 2006, prior to the passage of GINA, in a 
general population survey administered by Cogent Research, 18% of 1000 respondents 
believed that there were laws to protect the privacy of genetic information (Cogent 2010). 
Astoundingly, their 2010 survey, conducted after the passage of GINA, showed that even 
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fewer (16%) believed that protective laws existed. Likewise, in 2011, an online survey of the 
general public found that only 8.8% of 295 respondents had ever heard of GINA (Huang 
2013). Similarly, in striking contrast to the public’s increasing knowledge about genomic 
advances, knowledge about the social implications of genetic testing, such as the potential 
impact on the ability to obtain health insurance, has lagged far behind (Haga 2013).
Even within a population for whom GINA would be expected to be highly relevant, many 
remain unaware of it. In one study, fewer than half of the asymptomatic individuals who had 
an expanded allele for Huntington Disease (HD) were familiar with the law, a far fewer 
number than the three quarters of them who were familiar with the Health Insurance 
Portability and Accountability Act (HIPAA) (Dorsey 2013). An Australian study of those at 
risk for HD found a similar lack of awareness about legislation that prevents employers and 
health insurers from accessing and using genetic information in that country (Goh 2013).
Family physicians appear to have a level of knowledge about GINA that lies between that of 
genetic counselors and the general public. In a 2010 study of family practitioners, 54.4% 
said they were unaware of GINA, 35.2% knew about GINA, but had no knowledge about 
any specific features, and 10.3% had basic knowledge of GINA and its specific protections 
(Laedtke 2010).
Given the relatively high levels of knowledge about GINA among genetic counselors and 
the relatively low levels among some physicians and the general public, genetic counselors 
could serve as a valuable source of information about the implications of both the privacy 
and nondiscrimination protections of the law.
Discussing genetic discrimination
Genetic counselors have an unparalleled opportunity and ability to disseminate accurate 
knowledge of existing protections of genetic information to their patients. Despite this 
opportunity, Pamarti found that fewer than half of the 257 counselors surveyed reported 
discussing GINA during a session (Pamarti 2011). In this sample, counselors only discussed 
the law if a patient specifically inquired about discrimination (Pamarti 2011). The same 
study showed that, perhaps not surprisingly, cancer genetic counselors reported discussing 
the possibility of genetic discrimination with their patients more often than counselors in 
other specialties; 68% as compared to 28% in pediatric and 11% in prenatal (Pamarti 2011).
Given the amount and complexity of genetic information that is typically conveyed during a 
session, suggesting that balanced information about legal protections and their limitations 
also merits inclusion may seem unrealistic. It may also be viewed as an unnecessary 
diversion given the lack of empirical evidence of discrimination. A concise discussion about 
the existence and scope of legal protections need not be a major focus of the session, but the 
failure to describe a realistic picture of the current legal landscape surrounding genetic 
information can cause future harm to patients and their families. There are several 
organizations and websites to which patients can be referred that provide more detailed 
information about GINA and the gaps in the law (Resources). Referring patients to these 
sources can help genetic counselors balance the time constraints of a session with their 
responsibility to present accurate information. It is important to realize that even when 
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patients do not ask questions about genetic discrimination, they may still have concerns. 
Simply discussing basic information about GINA has been reported to lower patient fears 
about potential discrimination (Allain 2012). Therefore, combining a brief overview of the 
current legal protections of genetic testing with a referral to resources that describe the gaps 
and the limitations of the law could be an efficient method that, at the very least, introduces 
patients to the existence of the law and its general provisions. Depending upon their 
circumstances, some patients may need more comprehensive information.
Genetic Discrimination Post-GINA
There continues to be anecdotal stories of genetic discrimination but data on the use or 
misuse of genetic information in employment and insurance are lacking and few additional 
empirical reports of genetic discrimination have been published in the six years since GINA 
became law. It is not clear if this sparse amount of data is due to lack of genetic 
discrimination overall or lack of collected evidence. Additionally, there are likely many 
more violations of GINA’s privacy provisions, in contrast to its anti-discrimination 
protections, in part because the public and provider awareness of these aspects is even 
lower. There have been several studies exploring the existence of genetic discrimination in 
life insurance, but due to limited methodological rigor and the few number of subjects 
studied, the validity of the conclusions remains uncertain (Joly 2013). Despite lack of 
empirical evidence that discrimination is occurring, fear of genetic discrimination remains a 
barrier to the uptake of genetic testing, even in a post-GINA world (Allain 2012). Therefore, 
the discussion between counselors and patients about the legal protections that exist remains 
both necessary and beneficial.
Case Studies
The following cases illustrate some common questions and fears that genetic counseling 
patients may have regarding the potential for discrimination and summarizes the relevant 
legal background. We use these cases to highlight particular features of the legal 
protections; however similar real life situations may have different outcomes if an 
individual’s insurance or employment falls under legal exceptions, since the determination 
of whether state or federal laws apply depends on individual circumstances.
Case study 1
A 38-year-old woman calls a genetic counselor because her mother, maternal aunt, and 
maternal grandmother all had breast cancer. She would like to schedule an appointment for 
risk assessment and to discuss options for genetic testing but is worried about the possibility 
of genetic discrimination if information about her family history is entered into her medical 
record. What information does the genetic counselor need to address this concern?
Legal Protections
Most genetic counselors know that GINA regulates how some employers and health 
insurance companies can use genetic information. They may not, however, fully appreciate 
how broadly GINA defines some crucial terms. “Genetic information,” as defined by GINA, 
includes not just genetic test results, but also family medical history, use of genetic services 
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– such as genetic counseling –, and participation in genetic research (GINA 2008). 
Therefore, those employers and health insurance companies regulated by GINA are banned 
from using the woman’s family medical history or the fact that she had a consultation with a 
genetic counselor to do the following: raise her premium rates, deny her health insurance, 
make adverse employment decisions against her, or otherwise discriminate against her.
GINA’s definition of “family member” is also very broad, and includes first, second, third, 
and fourth degree relatives – all the way back to great, great-grandparents, and includes first 
cousins once-removed (CFR 2013). An individual’s genetic information, therefore, includes 
manifested conditions in any of these relatives.
In this case, the counselor could reassure the woman that employers and health insurers 
regulated by GINA would be banned from discriminating against her because of her 
relatives’ diagnoses of breast cancer. Additionally, her session with a genetic counselor 
would also be classified as “genetic information”, so the appointment itself – regardless of 
whether she decides to have genetic testing or not – is also protected information that cannot 
be used to discriminate. There are situations, especially when medical records are requested, 
in which an employer or health insurance company can obtain genetic information, 
including family history. These circumstances will discussed further later, but, in all 
situations, even if a covered entity learns of genetic information, it cannot use this 
information to discriminate.
Case study 2
A couple consults with a genetic counselor because the woman, who is fifteen weeks 
pregnant, had fragile X testing. Her results showed that she is a carrier and has a pre-
mutation of 78 CGG repeats in the FMR1 gene. The couple is worried that her employer or 
health insurer may be able to use the results of the test to discriminate against her even 
though she has no signs of premature ovarian insufficiency (POI); a condition associated 
with carrier status. They are also concerned about potential discrimination against the fetus, 
should they decide to have prenatal testing and find out the fetus has inherited the 
expansion. What information does the genetic counselor need to address these concerns?
Legal Protections
GINA includes a specific provision to emphasize that the genetic information of a fetus is 
considered part of the genetic information of the pregnant woman (GINA 2008). Therefore, 
in this situation, any genetic information discovered during prenatal testing would be 
considered the mother’s genetic information under GINA. After the baby is born, any testing 
done during pregnancy would also still be considered his or her own genetic information.
The association of expanded repeats in the FMR1 gene with an increased risk for POI as 
well as the fragile X tremor and ataxia syndrome (FXTAS) highlights one of the legal 
thresholds or limitations of GINA. Although the law protects against discrimination on the 
basis of genetic information, this protection does not extend to “manifested conditions”. The 
genetic information is protected under the law, even if symptoms begin, but the symptoms 
themselves are not protected. For example, in this case, the woman’s carrier status is 
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protected genetic information. However, if she begins to have symptoms of either premature 
menopause or FXTAS, GINA would no longer protect her from being discriminated against 
because of these symptoms. Even after her symptoms develop, however, covered employers 
or health insurance companies could not cite her carrier status as the reason for an adverse 
decision. As genomic sequencing becomes more commonly performed, this category of 
individuals, those who are asymptomatic but who are at risk for multiple phenotypes, could 
become more prevalent as the pleiotrophic effects of genomic variants become increasingly 
recognized (Kocarnik 2014).
To determine whether a covered employer or health insurer could use, for example, the 
woman’s premature menopause symptoms to legally discriminate, it is necessary to look to 
other laws. The Patient Protection and Affordable Care Act (ACA) currently makes it illegal 
for health insurers to deny health insurance or raise premiums based on a pre-existing 
condition (Patient Protection and Affordable Care Act of 2010) for adults. Genetic 
information is explicitly not considered a pre-existing condition under GINA (GINA 2008). 
Therefore, protections under GINA and the ACA meet at the point when a person manifests 
symptoms that could reasonably lead to diagnosis (Figure 1). A health insurer would be 
prohibited from using the woman’s carrier status to discriminate under GINA, but also 
would be prohibited from using her symptoms to discriminate under the ACA.
Legal protections in the employment arena are less comprehensive as compared to those 
applicable to health care. The Americans with Disabilities Act (ADA) protects against 
discrimination on the basis of a disability. In order for medical symptoms to be protected 
under this law, they must meet specific criteria. A “disability” is defined as “a physical or 
mental impairment that substantially limits one or more major life activities, a record of such 
an impairment, or being regarded as having such an impairment” (ADA 1990, ADAAA 
2008). Some symptoms and conditions will not fall under the definition of disability if they 
do not create a substantial limitation for the individual. Therefore, for some conditions, a 
gap remains between the legal protections of GINA and the ADA against employment 
discrimination (Rothstein 2008).
The symptoms of FXTAS and POI could potentially fall under the ADA, although this 
depends upon how the symptoms affect the individual. For example, an ataxia may 
substantially limit the major life activity of walking and POI may substantially limit the 
major life activity of reproduction. However, in the early stages, the symptoms may not 
reach the level of a substantial limitation and therefore not yet rise to the level of a disability 
under the ADA. It is possible that, in this circumstance, the woman’s employer could legally 
fire her based on early symptoms, although legal counter-arguments could be made under 
the ADA, especially under the ‘regarded as’ portion of the definition (Rothstein 2008).
Case study 3
After his 49-year-old father died of liver failure, a 20-year-old man becomes convinced that 
the cause was undiagnosed hemochromatosis and wonders about his own risk of this 
condition. He asks his primary care physician about the option of genetic testing and the 
physician orders HFE gene testing. The results showed that the man is homozygous for the 
deleterious Cys282Tyr mutation.
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Since requesting the test, the man has read about the possibility of discrimination based on 
the results of genetic testing. He is now concerned because he is applying for a new job and 
he doesn’t want a prospective employer or health insurance company to discriminate against 
him based on the results of his genetic test. He has told his physician that he doesn’t want to 
know his results until he gets a new job. The primary care provider calls a genetic counselor 
for advice. What information does the genetic counselor need to address these concerns?
Legal Protections
Although heralded as “the first civil rights bill of the new century” (CGF 2008), GINA 
extends the definition of anti-discrimination far beyond society’s colloquial meaning of the 
concept. GINA bans covered health insurers and employers, not just from using genetic 
information to harm an individual – in most instances it also prevents these actors from 
collecting genetic information in the first place (GINA 2008). Genetic information includes 
the results of a genetic test, such as the HFE gene testing in this case. It is important to note 
that the definition of genetic testing itself extends beyond single gene, highly penetrant 
disorders – even though these are the examples that are most often used. A genetic test is 
defined as “an analysis of human DNA, RNA, chromosomes, proteins, or metabolites that 
detects genotypes, mutations, or chromosomal changes” (GINA 2008). This definition 
would extend to many other situations such as learning about carrier status for an autosomal 
recessive disorder. Additionally, the definition does not depend upon when the genetic test 
was done or who performed it, so direct-to-consumer genetic tests, tests ordered by 
physicians and other healthcare professionals, and tests completed prior to the passage of 
GINA, in 2008, all would be protectable under the law.
The term “collection” in GINA encompasses requesting, requiring, or purchasing an 
individual’s genetic information – including any family medical history. Although covered 
health insurance companies are generally prohibited from collecting genetic information, in 
reality, as described above, they often gain access to genetic information through requests 
for medical records. GINA requires that all requests for medical records state that no genetic 
information should be included in the request, unless it is directly related to a payment 
determination (GINA 2008). The law then places the onus on the healthcare professional to 
redact out all genetic information from the copy of the medical record to be submitted to the 
insurer. Redaction does not mean removal of the information from the original medical 
record. Rather, it is the removal or masking of information from the copy of the medical 
record that is being transmitted to the requesting insurance company or employer. Redaction 
probably occurs infrequently due to the voluminous amounts of genetic information, 
including family medical history, sprinkled throughout medical records.
Patients could collaborate with healthcare professionals to attempt to limit the amount and 
type of genetic information inadvertently given to health insurers by focusing on redacting 
information that is of particular concern to the individual. Ideally, it has been suggested 
genetic information could be kept in a separate section of the medical record that is not 
provided to health insurers or employers that are covered by GINA and requires a separate 
consent to obtain (Prince 2012).
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It is important to appreciate GINA’s expansive definition of genetic discrimination for two 
reasons. First, the broader conceptualization of what counts as discrimination under the law 
means that genetic discrimination for which an individual could bring a complaint likely 
occurs at a much higher rate than is currently acknowledged. Imagine the difference in the 
response to a survey question asking individuals whether or not they have ever been denied 
insurance, fired from a job, or otherwise adversely affected based on their genetic 
information versus one that asks if a health insurance representative or employer has ever 
requested genetic test results or, even more likely, family history information from them. 
The second question is much more likely to garner a positive response; however, both 
instances are equally illegal and actionable under GINA. Both health professionals and the 
general public generally remain unaware that it is illegal for some entities to request genetic 
information, including family medical history and, furthermore, that in those instances, 
individuals can legitimately decline these requests thereby protecting the privacy of this 
information.
Secondly, the prophylactic ban on collection of genetic information by covered health 
insurers and employers places the patient in an unusual position of power. Lawsuits are 
incredibly time consuming, costly, and – especially in the case of employment and health 
insurance – very difficult for a plaintiff to win. In part, this is because it is relatively easy for 
an employer or health insurance company to invent reasons for a denial that mask the true, 
underlying reason of genetic discrimination. In one example, an insurance company denied a 
woman health insurance coverage because it was stated that her weight was slightly too low 
and she took birth control. The insurance denial also mentioned that she had had a 
prophylactic surgery – indicating that the stated reasons of low weight and being on birth 
control could have been proxies for genetic discrimination. The recent changes banning 
health insurance denials based on pre-existing conditions under the ACA now make this 
type of proxy reasoning unlikely to be effective in the health insurance arena.
Proxy genetic discrimination remains a risk in the employment cases– especially if an 
individual is considered to be an “at-will” employee. In this type of employment, an 
employee can be fired for “any reason or no reason” – as long as it is not a discriminatory 
reason (Guz 2000). This rule makes employment cases very difficult for employees to win 
since a savvy employer can easily hide a discriminatory intent for the adverse decision. In 
the case described above, it would be difficult for the man to know if he had been victim of 
genetic discrimination if he was not hired for a job for which he applied. Employers do not 
generally tell a person why he or she was not hired, so discriminatory intent can be very 
difficult to prove.
The enforcement mechanisms for health vs. employment claims under GINA are different. 
Individuals who believe that they have been discriminated against in employment can file a 
complaint with the Equal Employment Opportunity Commission (EEOC). Once individuals 
have exhausted the EEOC’s administrative process, they can litigate in federal court. In 
some cases, the EEOC will litigate a complaint that has been filed on behalf of the 
individual. For example, the EEOC recently settled with Founders Pavilion, a nursing and 
rehabilitation center, and the company agreed to pay $370,000 because they collected family 
history as part of a medical exam for new hires (EEOC 2014).
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It is much more difficult to uncover the number and types of complaints about genetic 
discrimination in health insurance because GINA’s enforcement provisions are tied to state-
specific procedures. If an individual feels that a health insurance company has violated his 
or her rights, he or she can file a complaint with the state department of insurance. Every 
state has a different agency and mechanism for these complaints, making it difficult to 
gather comprehensive data. The current evidence of genetic discrimination in health 
insurance remains anecdotal, just as it was prior to GINA. However, given the broad 
definition of genetic information and the ban on collecting genetic information, genetic 
discrimination – as defined by GINA – likely occurs much more often than people realize or 
report.
Realistically, patients may opt not to enforce their legal rights because of the hassles and 
cost of appeals and litigation. An individual may decide that this process is too costly, both 
financially and emotionally, as compared to a monthly premium rate increase. Avoiding 
legal action is an understandable decision for many individuals – and unfortunately in some 
cases, a necessity, when the cost of litigation is prohibitive. Therefore, knowledge that 
GINA bans the collection of genetic information is an important and powerful tool for 
individuals that enable them to help prevent genetic discrimination from occurring in the 
first place.
In contrast to genetic status, the nature of the bias in most forms of discrimination is 
generally readily apparent – one can often tell an individual’s race and gender, and 
sometimes even a person’s religion or disability, simply by looking at them. However, 
genetic information, in the absence of manifested symptoms, is never obvious just from 
looking at an individual. Therefore, if an individual can prevent an employer or health 
insurance company from obtaining information about his or her genetic status, he or she can 
prevent the possibility of subsequent genetic discrimination based on that information.
One of the most practical steps individuals can take is simply to refuse to answer general 
questions about their genetic information – including family medical history – that is asked 
by a covered health insurance representative or employer. Sometimes, even though 
questions about family medical history are not asked on the application, a representative 
from the company may ask these questions over the phone if they have not been properly 
trained on the law. Similarly, a covered employer may ask about family medical history or 
other genetic information during medical examinations or in other situations. The questions 
in both of these instances would likely be illegal; however they are still routinely being 
asked. The man concerned about his genetic test result for hemochromatosis could simply 
refuse to answer requests by a health insurance company or by his potential employer if 
either is a “covered entity”. This action stops the company from gaining access to his 
genetic information and therefore prevents genetic discrimination before it can occur.
Some Exceptions to GINA’s Ban on Collection of Genetic Information
It is important to note that there are several exceptions that allow companies to collect 
genetic information. As stated above, health insurance companies are permitted to request 
genetic information if it involves their decision about whether or not to pay for a medical 
procedure. For example, if the cost of the genetic testing for hemochromatosis was billed to 
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his health insurance, the company can ask the man for family medical history, such as the 
father’s liver disease, to show that testing was medically necessary. Similarly, if a woman’s 
BRCA sequencing is negative and her genetic counselor recommends BART testing, the 
health insurance company could request the initial test results. In these cases, the insurer can 
only ask for the minimum amount of information necessary to make their determination. 
Additionally, these insurers are not permitted to use the collected genetic information to 
discriminate.
The employment setting represents a less protected environment than that of health 
insurance and there are several additional exceptions to the prohibition on collecting genetic 
information. These exceptions include inadvertent acquisition, a voluntary disclosure by the 
individual as requested by a “wellness” program, any publicly available information, 
disclosure via a family and medical leave request, information requested for law 
enforcement purposes, and requests made as a part of a company’s toxic substances 
monitoring. For the most part, individuals can most easily prevent an employer from gaining 
access to genetic information in each of the first three exceptions by not discussing genetic 
information at work, refusing to answer questions about genetic information, including 
family history, during enrollment and participation in wellness programs, and by limiting the 
amount of genetic information publicly available, such as that posted on social media.
Genetic counselors can educate patients by explaining the circumstances under which they 
do not have to provide information about genetic tests and family medical history to covered 
health insurers and employers. With this knowledge, patients can take simple, specific steps 
to help prevent genetic discrimination before it occurs. In the case above, the man can 
decline to answer questions about his genetic information, including his family history, to 
potential employers, and, if he insists on posting information about his genetic status on 
social media sites and blogs, he should, at the very least, restrict the accessibility of others to 
these sites. These steps can help to protect him against discrimination based on genetic 
information in the employment and health insurance settings.
Case study 3 revisited
After hearing about the steps he can take to limit the amount and nature of the genetic 
information disclosed to a prospective employer, the man says, “Great because the job I 
really want is with a small start up company that has only 10 employees.” What information 
does the genetic counselor need to address this statement?
Legal Protections
GINA prohibits only certain kinds of entities, namely some health insurers and some 
employers, from using genetic information to discriminate against individuals (GINA 2008). 
Many private health insurers in the US are included under GINA’s umbrella and some that 
are excluded, such as the Federal Employee Health Benefits Plan, Tricare, Veteran’s Health 
Benefits, and the Indian Health Service, have their own restrictions against use of genetic 
information. Since these health insurers are group plans, they do not take any medical 
information, including genetic information, into account when setting rates and eligibility. 
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GINA does not extend to insurance companies that provide life, long-term care, or disability 
insurance nor does it apply to other entities such as education or licensing.
Many employers, including state, local, and some private employers, are included under 
GINA but the law does not apply to federal government employees and members of the 
military that have their own rules about what constitutes genetic discrimination (NHGRI 
2014). Laws covering federal employees broadly ban employment discrimination based on 
genetic information but they do not include the privacy protections of GINA. Military rules 
are less protective and allow some use of genetic information in employment decisions, such 
as the military’s prerogative to decide upon service placement based on genetic 
susceptibilities to disease (NHGRI 2014, Baruch 2008). For example, some branches use the 
results of genetic testing to make specific assignments to avoid adverse events (Baruch 
2008). Members of the military can refer to their employment policies to determine whether 
their branch provides information regarding genetic information, discrimination, and 
employment.
In the private sector, employers with fewer than fifteen employees do not have to comply 
with GINA. This segment accounts for about 15% of the US workforce leaving a substantial 
minority of workers without federal-level protections against genetic discrimination in 
employment (SBA 2011). Some of these workers are still protected against genetic 
discrimination at the state level and several states extend the employment protections to 
include businesses with fewer than fifteen employees (NCSL Jan. 2008). Therefore, these 
individuals have some state protections against genetic discrimination but these are typically 
not as broad as the federal level protections.
State Laws Covering Gaps in GINA
GINA creates a baseline of protection and, importantly, does not pre-empt stronger state 
laws. Therefore, individuals who work for a private employer with more than 15 employees 
may have the choice to file a complaint under either state or federal law. However, state 
laws are typically not as robust as GINA and the protections and the enforcement 
mechanisms against infractions vary greatly. For example, the size of employer that must 
comply with state statutes varies and is state law-dependent. Most notably, many state laws 
that “protect” against genetic discrimination in employment do not include the powerful 
prohibition that GINA has against the collection of genetic information. Some states do 
incorporate the broader protections by legislating that the entities that must comply with 
state law, must also comply with GINA.
As an example, if the man in this case was applying to a Californian employer with only ten 
employees, GINA would not apply, but Cal-GINA, a recently passed state law, may be 
applicable (Cal-GINA 2011). Cal-GINA applies to employers with five or more employees 
and, although it bans genetic discrimination, it does not prohibit those employers from 
collecting genetic information. Therefore the man would not enjoy the broader privacy 
protections of GINA in this case, but he would still be protected from genetic 
discrimination. He can still take steps to limit a prospective employer’s access to his genetic 
information, such as limiting public access via social media, but a small business employer 
could be allowed to ask about his genetic information directly. Importantly, however, even if 
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he were asked for this information directly, in California, the small business employer would 
be banned from using that information to discriminate against him.
A comprehensive discussion with genetic counseling patients about their legal protections 
becomes even more difficult because of the familial nature of genetic information. If a 
patient works for a large employer who offers health benefits, it may be tempting for the 
genetic counselor to paint broad-brush strokes and briefly note that GINA protects him or 
her against genetic discrimination. However, there are two serious flaws in this approach. 
First, it is likely that an individual, especially a younger patient, will switch jobs, be covered 
under different insurance companies, and/or move across state lines during his or her 
lifetime. These changes could affect his or her current legal protections because of gaps in 
the law. Secondly, the genetic information of an individual could impact others in the family 
and it is likely that some of these relatives will have different legal protections based upon 
where they live or who employs them. Genetic counselors can consult guides such as the 
Council for Responsible Genetics (CRG) to identify the protections afforded by a specific 
state. Determining whether or not specific state laws apply to employers that operate across 
state lines is often very complicated.
Case study 2 revisited
After the delivery of their son, the couple call the genetic counselor and explain that they 
want to obtain life insurance so that they can be assured that their children will be provided 
for should anything happen to them. They ask if the woman’s risk for POI and FXTAS will 
be considered pre-existing conditions in their life insurance application. In addition, the 
man’s father has recently developed symptoms of Alzheimer disease (AD). They have 
learned about the option of APOE testing and wondered about the implications if the man 
has this testing. What information does the genetic counselor need to address this statement?
Legal Protections
One of the most notorious gaps in GINA is that it does not apply to three types of insurance 
that individuals with genetic conditions may greatly desire; namely, life, long-term care, and 
disability insurances. Patients who discover they have a predisposition for cancer, AD, or 
other chronic illness are likely to seek insurance coverage to pay for nursing home care or to 
provide for their family when they pass away. At the same time, life, long-term care, and 
disability insurance companies are likely to seek information about an applicant’s risk level 
in order to make the best economic decisions for the company. In the vast majority of cases, 
these insurances can legally use genetic information in coverage decisions and could even 
require that an individual take a genetic test before deciding whether or not to cover them 
(Schultz 2013).
Although it is true that GINA does not apply to these three types of insurances, some state 
laws regulate the use of genetic information in these arenas (NCSL May 2008). All laws, 
however, are not created equally and it is important for patients and genetic counselors to 
refrain from equating the existence of a law with adequate protection. For the most part, 
states only regulate the use of genetic information in these insurances – not ban the use. For 
example, some state laws simply require that insurance companies show actuarial 
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justification for charging different premium amounts or for denying coverage (NCSL May 
2008). Actuarial justification requires insurers to show that their premium rates are 
reasonable given their expected costs – a task that is fairly straightforward if an individual 
has a genetic pre-disposition to a health condition because of the implication that expected 
costs will be higher. Therefore the requirement of actuarial justification does not protect 
individuals in the same way that the public commonly conceptualizes the word “protection”.
In other states, the laws regulating the use of genetic information in life, long-term care, and 
disability insurance simply requires “informed consent” from the enrollee when and if the 
insurance company requires a genetic test (NCSL May 2008). These laws do not prevent 
insurers from gathering genetic information and making coverage decisions based upon the 
information. For example, New Jersey’s law prohibits ‘unfair’ genetic discrimination in life 
insurance but this legally translates to requiring actuarial justification to use genetic 
information and obtaining “informed consent” from the individual prior to performing a 
genetic test (New Jersey Code 2008).
Finally, GINA broadly defines “genetic information” to include family medical history, use 
of genetic services, and participation in genetic research (GINA 2008). However, most state 
laws were passed prior to GINA and so define “genetic information” much more narrowly; 
namely, as genetic test results (NCSL May 2008). California’s law is an exception and 
includes family medical history in its expansive protection against discrimination in life, 
long-term care, and disability insurance (Cal-GINA 2011).
Unfortunately, the patchwork of state laws in life, long-term care, and disability insurance 
provides little concrete protection for individuals in these arenas. As new state laws continue 
to be passed, patients and genetic counselors must look carefully at the protections and 
should not assume that the laws are as comprehensive as GINA.
Options for Access to Supplemental Insurance
The lack of comprehensive protection at the state level, unfortunately, creates a difficult 
decision for individuals who are considering testing and yet are concerned about the 
possibility of genetic discrimination. One often-advised option is to secure coverage prior to 
having genetic testing although this approach has limitations as described in the next 
section. Additionally, if an individual is denied life, long-term care, or disability insurance, 
he or she should check the relevant state law to see if it is possible to appeal the decision 
(CRG resource). Although state laws vary, individuals have won appeals for denials based 
on genetic information, especially in states with more protective coverage, like California. 
Finally, policy makers at the federal and state level are increasingly considering legislation 
to improve access to these insurances for individuals with genetic conditions. Individual 
experiences and stories can be invaluable information to share with policy makers to 
increase their understanding about how current industry practices are affecting the public.
In the case study above, life, long-term care, and disability insurance companies may be able 
to deny the couple coverage based on genetic information – depending on which state they 
live in. In this situation, the genetic counselor could advise the couple to find out more about 
their state law by referring to a credible resource (CRG, NCSL, or consulting with an 
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attorney specializing in insurance law). It could be more difficult for the man to secure 
insurance due to his family history of AD because his case appears to present a stronger 
actuarial justification for increased costs. The man could consider getting insurance 
coverage prior to genetic testing, although in many states, the insurers would be allowed to 
ask about the family history, ask about genetic test results, and in some situations, require 
him to have genetic testing before making coverage determinations.
Fraudulent Information
When completing insurance applications or otherwise providing information to insurance 
companies, it is important that individuals be warned against committing fraud or lying on 
their applications. Unfortunately, it is not uncommon for patients to be incorrectly advised 
that, as long as a genetic test result is not in the medical records, they can state to an 
insurance company that they have not been tested. This ill-advised tactic can create 
substantial problems for them in the future. For example, if a long-term care insurer 
discovers that an individual committed fraud on an application, they can likely revoke the 
coverage and past reimbursements. If this discovery occurs after an individual has been in a 
nursing home for a number of years, it can result in a considerable financial obligation that 
the patient will then owe to the facility since the insurance is very likely to retroactively 
revoke past reimbursement payments.
Similarly, although GINA shields individuals from disclosing genetic information to health 
insurers and employers in most cases, it does not sanction fraud. If, in violation of GINA, a 
covered entity asks for genetic information, the appropriate response would be not to lie 
about testing results or family history, but rather to choose not to answer these questions.
Conclusion
It is a promising sign that there have been increasing numbers of both state and federal laws 
passed to protect individuals from genetic discrimination. The resulting patchwork of 
legislation, however, creates important gaps relevant for genetic counselors and their 
patients (Figure 2). The limited awareness of these laws, by both the public and health care 
professionals, greatly restricts their potential effectiveness. It is crucial that patients have 
access to credible information about the existing laws, as there may be actions they can take 
to help protect their genetic information and lower their risk of genetic discrimination, 
thereby preventing future harm to themselves and their families. Genetic counselors have 
both the unprecedented opportunity and the professional responsibility to disseminate 
accurate knowledge of existing legal protections to their patients. By acquiring additional 
knowledge of how these protections might apply to their practice, genetic counselors could 
help ease some unfounded concerns about possible discrimination and enlighten patients 
about actions they can take to help protect their genetic information, wherever possible.
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Application of GINA and the ADA in the continuum from asymptomatic genetic 
information to manifested disease
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Figure 2. Protections of the Collection and Use of Genetic Information (GI) by Entity
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